About Superluminal Medicines:
Superluminal Medicines (Superluminal) is a generative biology and chemistry company revolutionizing the speed and accuracy of how small molecule medicines are created. The Company’s platform aims to create candidate-ready compounds with unprecedented speed using a combination of deep biology, computational and medicinal chemistry, machine learning, and proprietary big data infrastructure. We are expanding the team of talented scientists who seek to build the future of small molecule drug discovery with creativity and innovation.
About the Role:
Superluminal Medicines, Inc. is seeking a skilled and collaborative Scientist/Sr. Scientist with a strong background in GPCR pharmacology and drug discovery to join our growing and dynamic Biology team. We are a biology-first drug discovery company harnessing artificial intelligence and machine learning (AI/ML) to address bottlenecks in drug development while seamlessly integrating biology, chemistry, and computation.
This role provides an exceptional opportunity to contribute to transformative drug discovery efforts, refine expertise in cutting-edge biology, and drive progress in addressing critical healthcare challenges worldwide.
Roles and Responsibilities:
- Design, develop, and perform in vitro screening and MOA assays with precision, ensuring high-quality data to support drug discovery programs.
- Troubleshoot experiments and analyze complex datasets with scientific rigor and integrity.
- Maintain meticulous documentation of experimental protocols and data, adhering to quality and regulatory guidelines.
- Collaborate with multidisciplinary teams, including computational biologists and machine learning scientists, to interpret and share experimental results.
- Develop and optimize experimental methods based on literature and emerging technologies.
- Present experimental findings and insights in team meetings to drive project milestones.
Requirements:
- PhD or MS in Pharmacology, Biochemistry, Biology, or a related field with 5+ years of laboratory experience in GPCR pharmacology or drug discovery.
- Extensive hands-on experience with biochemical, cellular, and/or binding assays, with a proven ability to deliver reliable and reproducible data.
- Expertise in GPCR biology and pharmacology is essential.
- Proficiency in laboratory techniques, including cell culture, reagent preparation, and the use of lab instrumentation/software.
- Ability to independently design experiments, analyze results, and troubleshoot effectively.
- Strong organizational skills, attention to detail, and a commitment to excellence in research.
- Exceptional communication and collaboration skills to thrive in a multidisciplinary environment.
- Bonus Qualifications:
- Experience with small molecule drug discovery.
- Exposure to in vivo pharmacology and animal studies (preferred but not required).
This is a lab-based position that requires a hands-on, innovative approach to advancing discovery efforts.
Equal Opportunity Statement:
Superluminal Medicines is an Equal Opportunity Employer committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status.
Top Skills
What We Do
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability.
With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP.
